MedTrace Logo

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

NCT01555112 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether the improved topical ointment formulation, AS101, is safe and effective in the treatment of external genital warts in females.

Conditions

  • Wart; External Genital Organs
  • Condyloma Acuminata

Interventions

DRUG

Topical AS101

AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.

Sponsors & Collaborators

  • BioMAS Ltd

    lead INDUSTRY

Principal Investigators

  • Shabtai Romano, MD · Ha'Emek Medical Center, Afula, Israel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01555112 on ClinicalTrials.gov